NATURE:不够高?你可能有FBN1错义变异体 

2020-05-14 MedSci原创 MedSci原创

就我们所知,这是已知的常见身高相关变异体中具有最大效应的基因突变。

平均而言,秘鲁人是世界上身高最矮的人之一。

最近,研究人员表明,美洲原住民血统与秘鲁人种群中的身高降低有关,并在FBN1基因中鉴定出一个与身高降低显著相关的人群特异性的错义变异体(E1297G)。

该罕见等位基因的每一个拷贝(频率为4.7%)都会使身高降低2.2厘米(纯合个体身高降低为4.4厘米)。

就我们所知,这是已知的常见身高相关变异体中具有最大效应的基因突变。

FBN1编码细胞外基质蛋白纤维素1,它是微纤维素的主要结构成分。研究人员观察到,与E1297纯合的个体相比,G1297纯合的个体皮肤中富含纤维蛋白1的微纤维蛋白密度较低,边缘不规则。

此外,研究人员表明,E1297G位点在非非洲人种群中处于阳性选择状态,而E1297变异体在秘鲁人种群中显示出微妙的阳性选择证据。

该变体在秘鲁沿海种群中的频率也明显高于安第斯山脉或亚马逊地区的种群,这表明身材矮小可能是适应秘鲁沿海环境相关因素的结果。

 

原始出处:

Samira Asgari et al. A positively selected FBN1 missense variant reduces height in Peruvian individuals. NATURE (2020). 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951301, encodeId=7f7919513015c, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 23 01:13:22 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813822, encodeId=ffee81382217, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:25:03 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884316, encodeId=a3e018843165f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 00:13:22 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342688, encodeId=d37d134268802, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat May 16 06:13:22 CST 2020, time=2020-05-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951301, encodeId=7f7919513015c, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 23 01:13:22 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813822, encodeId=ffee81382217, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:25:03 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884316, encodeId=a3e018843165f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 00:13:22 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342688, encodeId=d37d134268802, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat May 16 06:13:22 CST 2020, time=2020-05-16, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1951301, encodeId=7f7919513015c, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 23 01:13:22 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813822, encodeId=ffee81382217, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:25:03 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884316, encodeId=a3e018843165f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 00:13:22 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342688, encodeId=d37d134268802, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat May 16 06:13:22 CST 2020, time=2020-05-16, status=1, ipAttribution=)]
    2020-12-29 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951301, encodeId=7f7919513015c, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 23 01:13:22 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813822, encodeId=ffee81382217, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:25:03 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884316, encodeId=a3e018843165f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 00:13:22 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342688, encodeId=d37d134268802, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat May 16 06:13:22 CST 2020, time=2020-05-16, status=1, ipAttribution=)]

相关资讯

Nature:揭示病毒起源,为药物与疫苗研发提供有力支持!明尼苏达大学李放教授团队揭示新冠病毒结合人体细胞的机制

2020年3月30日明尼苏达大学李放教授团队发表题为“Structural basis of receptor recognition by SARS-CoV-2” 的《Nat

Preprints:中科院:无证据表明亚洲人新冠病毒细胞通道ACE2受体表达量更高

近日,中科院遗传与发育所的钱文峰团队在证实肿瘤与ACE2受体表达无关后通过包括TCGA(癌症基因组图谱)在内的大量癌症基因组研究数据库中人类不同组织ACE2受体表达水平比对,发现与其余种族相比在亚洲人中ACE2的表达并无显着差异,然而其表达却与年龄呈正相关。

化疗引发基因突变?癌症治疗毒副作用关键机制首次揭秘!

化学疗法的问世曾一度改变了癌症患者的治疗格局,大大降低了癌症患者的死亡率。在现今的各类癌症治疗技术中,化疗可以说是所有治疗的基石。化疗属全身性治疗方法,它通过阻止癌细胞生长和分裂来发挥作用,由于癌细胞通常比正常细胞生长和分裂速度更快,因此化疗对癌细胞的影响更大。适用于大部分肿瘤,早期、中期、晚期患者均需要化疗,特别是化疗敏感的肿瘤,如淋巴瘤、白血病等,能有效延长生存期,甚至能治愈某些癌症。这是它起

JASN:基因突变在肾脏疾病中的作用

导言:肾病综合征是小儿泌尿系统疾病中的常见病。临床上表现为大量蛋白尿、低白蛋血症、水肿和高脂血症。其病因和发病机制尚不清楚。一般认为免疫因素和炎性损失在发病中起主要作用。

病毒、细菌和基因突变,谁是你很大的敌人?

30亿~40亿年前,生命始祖——细胞诞生了。自此,生命向着多样化和复杂化演化。但病毒是个奇葩,它向简单化发展。病毒放弃它不需要的一切,只剩下蛋白质外壳及其里面的核酸。病毒就像海盗,“劫持”细胞,在宿主细胞中生存和繁衍。对生命来说,病毒仿佛一种生存压力。在这种压力之下,弱者淘汰,适者生存。为了对抗敌人,生命诞生了防卫系统——免疫系统。在病毒等多种病原体的刺激下,免疫系统不断进化。病毒还是“基因快递员

Nat Genet:化疗引发基因突变?癌症治疗毒副作用关键机制首次揭秘!

导语:一直以来,诸多关于癌症的研究都是围绕基因突变如何导致癌症而展开,却鲜有关于癌症治疗导致基因突变的研究报道,近期,由ICREA研究员、生物医学研究所生物医学基因组学实验室主任、庞培法布拉大学助理教授Núa López-Bigas领导的研究小组首次描述了用于治疗癌症的6种疗法引起的基因改变(5种基于化学疗法的药物和放疗),该研究结果已同步在《自然遗传学》杂志上发表。